BioRestorative Therapies, Inc. (NASDAQ: BRTX) saw a significant rise in its stock performance today, closing the trading session at $1.9500 with a gain of $0.6150, or 46.07%. Despite this substantial intraday increase, the stock experienced a slight dip in after-hours trading, falling by $0.10 or about 5.14%, to $1.8498. Throughout the day, the stock fluctuated between $1.6200 and $2.3200, indicating high volatility. Trading volume was notably high, with 93,374,088 shares changing hands, significantly surpassing the average volume of 2,029,382. This surge in trading volume and price movement could reflect investor reactions to recent company announcements or broader market conditions. The market cap stood at approximately $13.201 million by the end of the day, highlighting the small-cap nature of the company in the biotechnology sector.
BioRestorative Therapies, Inc. (“BioRestorative” or “BRTX”), a NASDAQ-listed clinical stage company, is making significant strides in the field of regenerative medicine through its innovative stem cell-based therapies. Today, the company announced ongoing discussions regarding the licensing of its ThermoStem® technology, a cutting-edge metabolic treatment platform, with an undisclosed commercial-stage regenerative medicine company.
ThermoStem® utilizes an allogeneic, off-the-shelf approach to treat metabolic disorders through the use of brown adipose tissue (BAT) derived stem cells (BADSCs). This technology leverages preclinical data, collaboratively studied with the University of Utah School of Medicine, which demonstrates that these stem cells are not only clonogenic and capable of expanding in vitro but also possess the ability to differentiate into various lineages including osteogenic, chondrogenic, and adipogenic paths. Most critically, these cells can functionally convert into metabolically active brown adipocytes.
The importance of BAT in metabolic regulation is well-documented, with its enhanced mitochondrial activity being pivotal in managing conditions such as obesity. In groundbreaking animal studies, BADSCs, when transplanted into high-fat fed NOD-SCID mice using a 3D Porous Extracellular Matrix-Derived Scaffold, exhibited significant improvements in weight, triglyceride, and blood glucose levels. These results underline the potential of ThermoStem® as a transformative treatment for obesity and related metabolic disorders.
Lance Alstodt, CEO of BioRestorative, expressed optimism about the rapid and robust interest from potential license partners. “Our pioneering studies have shown promising results in correcting weight gain and hyperglycemia associated with high-fat diets. The robust functionality of our 3D scaffolds, capable of sustaining viable transplanted cells for extended periods, has attracted a significant partner for potential licensing discussions,” he stated.
About BioRestorative Therapies, Inc.
BioRestorative Therapies (www.biorestorative.com) is committed to developing cell-based therapeutic products, focusing on adult stem cell protocols. The company’s core clinical programs are geared towards the treatment of disc/spine disease and metabolic disorders:
- Disc/Spine Program (brtxDISC™): The leading candidate, BRTX-100, is designed for the non-surgical treatment of painful lumbosacral disc disorders using a patient’s own cultured mesenchymal stem cells. A Phase 2 clinical trial is currently evaluating BRTX-100 for chronic lower back pain due to degenerative disc disease.
- Metabolic Program (ThermoStem®): This program targets obesity and metabolic imbalances using BADSC to create BAT, aiming to harness its natural metabolic regulatory benefits.
Furthermore, BioRestorative also runs a BioCosmeceutical platform, producing products such as cell-based serums that target cosmetic concerns like fine lines and wrinkles. With ongoing IND-enabling studies, the company is exploring the expansion of this platform to include a broader array of biologic aesthetic products, aiming for future FDA approvals in the burgeoning BioCosmeceuticals space.
As BioRestorative moves forward with its licensing discussions, the healthcare industry watches closely, anticipating a new era of treatments that harness the power of regenerative medicine to tackle some of the most challenging medical conditions.
